GlassScriptPhysician profile
Aanchal Jain
NPI 1295997625
$5,953.96
in general payments reported to CMS, 2019-2025
41 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,673 · 2020: $730 · 2021: $435 · 2022: $676 · 2023: $1,204 · 2024: $683 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,439.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,151.22 | 2021-2025 | |
| Eisai INC. | $408.39 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $401.20 | 2019-2020 | |
| Lilly USA, LLC | $295.17 | 2019-2024 | Kisunla, Emgality, Reyvow |
| Merz Pharmaceuticals, LLC | $279.77 | 2021-2024 | Xeomin |
| Allergan, INC. | $275.30 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $244.27 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $237.77 | 2019-2022 | |
| Ge Healthcare | $218.55 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $204.18 | 2019-2022 | |
| Genzyme Corporation | $191.23 | 2019-2023 | |
| Ucb, INC. | $189.56 | 2019-2021 | |
| Mentor Worldwide LLC | $183.25 | 2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Lundbeck LLC | $176.45 | 2022-2024 | Vyepti, Rexulti |
| Jazz Pharmaceuticals INC. | $153.08 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aanchal Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.